Table. Immune-Mediated Toxic Effects Possibly Related to Ipilimumab for Run-in Phase 1 and Phase 2.
Adverse Event | Patients, No. (%) | |
---|---|---|
All Grades | Grade ≥3 | |
Diarrhea | 12 (29) | 4 (33) |
Colitis | 2 (5) | 1 (50) |
Enterocolitis | 1 (2) | 1 (100) |
Pancolitis | 1 (2) | 1 (100) |
Colonic perforation | 1 (2) | 1 (100) |
Maculopapular rash | 12 (29) | 1 (8) |
Pruritus | 9 (21) | 1 (11) |
Increased aspartate aminotransferase | 9 (21) | 1 (11) |
Increased alanine aminotransferase | 9 (21) | 0 |
Arthralgia | 3 (7) | 1 (33) |
Peripheral neuropathy | 2 (5) | 0 |
Hypothyroidism | 2 (5) | 0 |